 |
53 Diseases |  |
490 Trials |
|
490 Trials |  |
8927 News |  |
| «12...100101102103104105106107108109110...123124» |
- || Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Biomarker, Clinical, P2 data, Journal, PD(L)-1 Biomarker, IO Biomarker: Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. (Pubmed Central) - Jun 18, 2020
P1b/2
Lenvatinib plus pembrolizumab showed anti-tumour activity in patients with advanced recurrent endometrial cancer with a safety profile that was similar to those previously reported for lenvatinib and pembrolizumab monotherapies, apart from an increased frequency of hypothyroidism. Lenvatinib plus pembrolizumab could represent a new potential treatment option for this patient population, and is being investigated in a randomised phase 3 study.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion: HOPE: Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer (clinicaltrials.gov) - Jun 17, 2020
P2, N=39, Completed, Sponsor: Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Lenvatinib plus pembrolizumab could represent a new potential treatment option for this patient population, and is being investigated in a randomised phase 3 study. Active, not recruiting --> Completed
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Trial completion date, Trial primary completion date, Monotherapy: Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials (clinicaltrials.gov) - Jun 16, 2020
P2, N=50, Active, not recruiting, Sponsor: Eisai Inc.
Active, not recruiting --> Completed Enrolling by invitation --> Active, not recruiting | Trial completion date: Sep 2020 --> Dec 2020 | Trial primary completion date: Sep 2020 --> Dec 2020
- || Clinical, Journal: First-line targ veted therapies of advanced hepatocellular carcinoma: A Bayesian network analysis of randomized controlled trials. (Pubmed Central) - Jun 14, 2020
Vandetanib seems to be the best choise with low quality of evidence. For better survival, novel targeted treatment options for HCC are sorely needed.
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical, Journal: Portal hemodynamic effects of lenvatinib in patients with advanced hepatocellular carcinoma: a prospective cohort study. (Pubmed Central) - Jun 11, 2020
For better survival, novel targeted treatment options for HCC are sorely needed. Considering that this was a short-term study, because lenvatinib could be an agent that aggravates portal hypertension, it will be necessary to verify its clinical effects for portal hypertension in future studies.
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
New trial, PD(L)-1 Biomarker, IO biomarker: PLENTY202001: Pembrolizumab and LENvatinib in Participants With Hepatocellular Carcinoma (HCC) Before Liver Transplant (clinicaltrials.gov) - Jun 11, 2020
P=N/A, N=220, Not yet recruiting, Sponsor: RenJi Hospital
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New trial, Checkpoint inhibition: Safety and Efficacy of Lenvatinib in Subjects With HCC Progression After First Line Treatment With Checkpoint Inhibitors (clinicaltrials.gov) - Jun 11, 2020
P, N=20, Not yet recruiting, Sponsor: Humanity & Health Medical Group Limited
- ||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Monotherapy, Metastases: Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009) (clinicaltrials.gov) - Jun 11, 2020
P2, N=400, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P1 trial: Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC) (clinicaltrials.gov) - Jun 11, 2020
P1, N=12, Not yet recruiting, Sponsor: University of Illinois at Chicago
- | Lenvima (lenvatinib) / Eisai, Merck (MSD), Sutent (sunitinib) / Pfizer, Nexavar (sorafenib) / Bayer, Amgen
Biomarker, Journal: Tyrosine Kinase Inhibitor-Induced Hypertension: Role of Hypertension as a Biomarker in Cancer Treatment. (Pubmed Central) - Jun 10, 2020
HTN may become a potential biomarker in clinical practice involving treating advanced cancers. However, data are currently limited by the number of studies and knowledge of the mechanism of action.
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical, Retrospective data, Journal, Real-World Evidence: Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy. (Pubmed Central) - Jun 10, 2020
Lenvatinib is active and safe in unselected, RAI-refractory, progressive DTC patients in real-life setting. RR and PFS seem to be less favourable than those observed in the SELECT trial, likely due to a negative selection that included heavily pretreated patients or with poor performance status.
- || Lenvima (lenvatinib) / Eisai, Merck (MSD), Nexavar (sorafenib) / Bayer, Amgen
Review, Journal: The Underlying Mechanisms of Noncoding RNAs in the Chemoresistance of Hepatocellular Carcinoma. (Pubmed Central) - Jun 9, 2020
A deeper understanding of the molecular mechanisms responsible for ncRNA-mediated drug resistance in HCC will provide new opportunities for improving the treatment of HCC. In this review, we summarize recent findings on the molecular mechanisms by which ncRNAs regulate HCC chemoresistance, as well as their potential clinical implications in overcoming HCC chemoresistance.
- | Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Journal: Current statuses of molecular targeted and immune checkpoint therapies in hepatocellular carcinoma. (Pubmed Central) - Jun 9, 2020
However, sorafenib, as the first approved systemic treatment in 2007, only increased overall survival by three months in advanced HCC patients...Lenvatinib acts as a first-line drug, whereas regorafenib, ramucirumab, and cabozantinib are defined as second-line drugs...Combined immunotherapies with matched molecular targeted treatments would be a novel breakthrough. Herein, we summarize the current statuses of immunotherapies and molecular targeted drug therapies, and mainly identify clinically feasible chemoimmunotherapeutic strategies.
- ||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, Metastases: Lenvatinib and Pembrolizumab in People with Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers (clinicaltrials.gov) - Jun 4, 2020
P2, N=64, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Herein, we summarize the current statuses of immunotherapies and molecular targeted drug therapies, and mainly identify clinically feasible chemoimmunotherapeutic strategies. Not yet recruiting --> Recruiting
- ||| Tevimbra (tislelizumab-jsgr) / BeiGene
Enrollment open: RATIONALE-211: Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma (clinicaltrials.gov) - Jun 3, 2020
P2, N=66, Recruiting, Sponsor: BeiGene
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New trial: Adjuvant Lenvatinib Prevents Recurrence of High-risk Patients With HBV-related HCC After Liver Transplantation (clinicaltrials.gov) - Jun 3, 2020
P, N=23, Completed, Sponsor: Jinyang Gu
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date, Metastases: Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma (clinicaltrials.gov) - Jun 2, 2020
P2, N=33, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Not yet recruiting --> Recruiting Trial completion date: May 2020 --> May 2021 | Trial primary completion date: May 2020 --> May 2021
- |||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
& most freq job post fda is pharma-- I am a believer that current FDA legal authority permits them to fix problems of 1. control arm 2. errors of X over 3. errors in drug dosing (axis/ lenvatinib HCC), 4. NI margins (too big) -- detailed in chap 14 of my book (Twitter) - Jun 1, 2020
- ||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Are they testing Pembro + Lenvatinib in mCRC as part of the LEAP studies? (Twitter) - May 31, 2020
- || Lenvima (lenvatinib) / Eisai, Merck (MSD), Nexavar (sorafenib) / Bayer, Amgen
Review, Journal: A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine. (Pubmed Central) - May 31, 2020
Lenvatinib could not reliably be compared with sorafenib. Choice of treatment is therefore likely to depend on an individual patient's circumstances.
- |||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical: I have only two left who are on it. I think lenvatinib is much more tolerable. I also like the enthusiasm of discussing third line in HCC, with many succumbing to declining liver function by the time a second line is through. (Twitter) - May 30, 2020
- |||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Lenvatinib + PD-1 seems like an answer for most GI cancers these days. Paper soon for gastric. @KoheiShitara (Twitter) - May 30, 2020
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Sounds more like Lenvatinib given the mechanism of action ( VEGF, PDGFR,c-kit and FGFR) Lenva appears to have RET activity too.. (Twitter) - May 30, 2020
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] Multicenter, real-world experience with lenvatinib for patients with advanced hepatocellular carcinoma in Japan (Poster Area) - May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-1907;
Lenvatinib showed high response rate and tolerability for patients with advanced HCC. Favorable outcomes were similarly observed even in patients who did not meet the REFLECT inclusion criteria.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] Relative dose intensity and response in real-world treatment with Lenvatinib for advanced hepatocellular carcinoma () - May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-1904;
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] Safety and efficacy of lenvatinib in Child-Pugh A and B patients with unresectable hepatocellular carcinoma in clinical practice (Poster Area) - May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-1893;
Lenvatinib treatment offers significant benefit in patients with good liver function in real- world practice. The various characteristics identified in this study might be helpful as clinicalpredictors of response to lenvatinib and survival in field practice.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] Early changes in circulating FGF19 and ANG-2 levels as a possible predictive biomarker for lenvatinib therapy in hepatocellular carcinoma (Poster Area) - May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-1880;
The various characteristics identified in this study might be helpful as clinicalpredictors of response to lenvatinib and survival in field practice. Early changes in circulating FGF19 and Ang-2 levels might be useful for predicting clinical response and PFS in HCC patients on lenvatinib therapy.
- Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
[VIRTUAL] Impact of a nurse educational program for patient empowerment during sequential systemic therapy for hepatocellular carcinoma (Poster Area) - May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-1222;
The dose-adjustments needed in the early phase and previous experience with sorafenib influence the nature of the calls received. The use of this educational tool during the systemic treatment sequence suggest a progressive empowerment of the patients and a more efficient use of resources.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] A phase 1b study of lenvatinib plus pembrolizumab in unresectable hepatocellular carcinoma (Channel 2) - May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-240;
P1b, P3
LEN + PEMBRO has promising antitumor activity with a tolerable safety profile. An ongoing phase 3 trial (NCT03713593) is assessing LEN + PEMBRO vs LEN alone as 1L therapy for uHCC.
- |||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical, P1 data: Very promising phase 1 data of #lenvatinib + #pembrolizumab in #Hepatocellularcarcinoma #HCC #livercancer with PFS = 9.3M, RR = 46% and median OS = 22M, fairly well tolerated. #ASCO2020 #CancerResearch #clinicaltrials #OncoAlert #cancer #Immunotherapy @VUMC_Cancer (Twitter) - May 30, 2020
- |||| 🥁 @ChungHanLee3 @sloan_kettering presents ph2 Lenvatinib + Everolimus in IO pre-treated clear cell #mRCC @ASCO #ASCO20 @motzermd @bilenma 👏👏 n=104 ORR 55% & 36% SD OS at 12 mos is 77% & mOS=NR Ph3 - Len/Eve or Len/Pembro vs sunitinib is ongoing (Twitter) - May 29, 2020
- ||||| Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical: Updated results of Ph2 KeyNote-146 w/ Pembro-Lenvatinib in mRCC patients 2L/3L. Prior regimens: anti-PD1/L1 (100%), Anti-PD1/L1+anti-VEGFR (65%) and Ipi-Nivo (37%). Very high ORR 55%, including all cohorts #ASCO20. Should this combo be tested in 2L/3L in Ph3 trials? (Twitter) - May 29, 2020
- |||| Halaven (eribulin mesylate) / Eisai, Lenvima (lenvatinib) / Eisai, Merck (MSD)
#ASCO20 Abstract 11507: A Ib/II study of the combination of lenvatinib (L) and eribulin (E) in advanced #liposarcoma and #leiomyosarcoma. Novel combination of a multitargeted TKI and microtubule inhibitor for L-type #sarcoma. @saxotomy Chen et al. @OncoAlert @NationalLMSF (Twitter) - May 29, 2020
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial primary completion date: A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China (clinicaltrials.gov) - May 27, 2020
P3, N=81, Active, not recruiting, Sponsor: Eisai Co., Ltd.
An ongoing phase 3 trial (NCT03713593) is assessing LEN + PEMBRO vs LEN alone as 1L therapy for uHCC. Trial primary completion date: Apr 2020 --> Jul 2019
- |||| Tevimbra (tislelizumab-jsgr) / BeiGene
New P2 trial: RATIONALE-211: Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma (clinicaltrials.gov) - May 26, 2020
P2, N=66, Not yet recruiting, Sponsor: BeiGene
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical, P2 data, Journal: Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma. (Pubmed Central) - May 23, 2020
This trial met the prespecified overall response rate primary end point, demonstrating antitumor activity with lenvatinib in R/M ACC patients. Toxicity was comparable to previous studies, requiring monitoring and management.
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion: KEYNOTE 523: Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors (clinicaltrials.gov) - May 22, 2020
P1b, N=6, Completed, Sponsor: Eisai Co., Ltd.
Toxicity was comparable to previous studies, requiring monitoring and management. Active, not recruiting --> Completed
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
First look at #lucitinib PD-1 combo is #ESMO20 now, interesting kinase inhibitory profile versus #lenvatinib, $clvs wild-card (Twitter) - May 21, 2020
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment change, Trial withdrawal: Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma (clinicaltrials.gov) - May 21, 2020
P2, N=0, Withdrawn, Sponsor: Sun Yat-sen University
Active, not recruiting --> Completed N=25 --> 0 | Suspended --> Withdrawn
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial initiation date, PD(L)-1 Biomarker, IO biomarker: NeoPele: A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma (clinicaltrials.gov) - May 21, 2020
P2, N=20, Not yet recruiting, Sponsor: Melanoma Institute Australia
N=25 --> 0 | Suspended --> Withdrawn Initiation date: Mar 2020 --> Aug 2020
- ||| Clinical: Happy to see the BCLC staging system in this relevant document. The key question is if there are data for assuming that sorafenib/lenvatinib are adequate second-line therapies after atezo-beva failure (same concerns with regorafenib, ramucirumab and cabozantinib in third-line) (Twitter) - May 20, 2020
- || Lenvima (lenvatinib) / Eisai, Merck (MSD), Nexavar (sorafenib) / Bayer, Amgen
Review, Journal: Angiogenesis in Hepatocellular Carcinoma; Pathophysiology, Targeted Therapy, and Role of Imaging. (Pubmed Central) - May 20, 2020
Several criteria can be used to assess response to treatment, such as quantitative perfusion on cross-sectional imaging and novel/emerging MRI techniques, including a host of known and emerging biomarkers and radiogenomics. This review addresses the pathophysiology of angiogenesis in HCC, accurate imaging assessment of angiogenesis, monitoring effects of anti-angiogenic therapy to guide future treatment and assessing prognosis.
- ||| Talzenna (talazoparib) / Pfizer, Lenvima (lenvatinib) / Eisai, Merck (MSD)
P2 data: ASCO2020 abstractを引き続き、読み漁ります。 本日は、poster discussionの乳がん再発治療編。 oral SERDの話題が2本 PARPi Talazoparibの効果予測因子に関する話題 免疫療法関連の試験はいまいちな結果が2本... Lenvatinib+LETのいい感じのphase2 その他色々... 以下、続。 #ASCO020 #ASCO2020 (Twitter) - May 20, 2020
- || Votrient (pazopanib) / Novartis, Lenvima (lenvatinib) / Eisai, Merck (MSD), Nexavar (sorafenib) / Bayer, Amgen
Clinical, Journal: The experience of an Endocrinology Division on the use of tyrosine multikinase inhibitor therapy in patients with radioiodine-resistant differentiated thyroid cancer. (Pubmed Central) - May 19, 2020
This review addresses the pathophysiology of angiogenesis in HCC, accurate imaging assessment of angiogenesis, monitoring effects of anti-angiogenic therapy to guide future treatment and assessing prognosis. Our study reflects the real-world clinical experience of an Endocrinology Division on the management of radioiodine-resistant DTC patients with sorafenib and lenvatinib, showing a beneficial therapeutic effect with acceptable tolerability.
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Metastases: Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma (clinicaltrials.gov) - May 18, 2020
P2, N=17, Not yet recruiting, Sponsor: Emory University
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
? Lenvatinib 2nd line (Twitter) - May 17, 2020
- ||| Atezolizumab/bevacizumab is likely to become the new frontline standard in unresectable HCC in the near future, says @DrElkhoueiry @KeckMedUSC. For the time being, however, sorafenib & lenvatinib remain the current standard of care. https://t.co/vEUt85948G (Twitter) - May 17, 2020
- In vitro validation of drug-target interactions revealed in silico by Comprehensive Resource of Biomedical Relations with Network Representations and Deep Learning (CROssBAR) in HCC (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_3789;
Our validation results have illustrated that the comprehensive CROssBAR tool developed by our research group achieved in vitro significant predictions of new drugs and their targets against HCC that were not previously reported. Hence with this study we were able to demonstrate the use and validity of the CROssBAR tool along with new targets for primary liver cancer therapeutics.
- Lenvima (lenvatinib) / Eisai, Merck (MSD), capecitabine / Generic mfg.
Final result of lenvatinib and capecitabine in combination with external beam radiation in treatment of locally advanced rectal cancer: Phase I clinical trial (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_3674;
The combination of lenvatinib and capecitabine plus radiation shows encouraging safety and efficacy results. Larger randomized study is warranted to verify our findings.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Inhibition of FGFR signaling by lenvatinib activates tumor interferon gamma signaling pathway and potentiates antitumor activity of anti-PD-1 antibody (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_2725;
Dual inhibition of VEGFR and FGFR signaling by LEN may exert the greater antitumor activity via activation of IFNγ pathway compared with single inhibition of VEGFR signaling in combination with PD-1 Ab. These results provide one of unique mechanisms of antitumor activity of LEN as VEGFR and FGFR inhibitor in combination with PD-1 blockade in preclinical models.